Core Viewpoint - BOK Financial (BOKF) reported quarterly earnings of $1.86 per share, missing the Zacks Consensus Estimate of $2.01 per share, and showing a decline from $1.91 per share a year ago, indicating an earnings surprise of -7.46% [1][2] Financial Performance - The company posted revenues of $502.29 million for the quarter ended March 2025, which was 3.13% below the Zacks Consensus Estimate, compared to $455.27 million in the same quarter last year [2] - Over the last four quarters, BOK Financial has surpassed consensus EPS estimates three times and topped consensus revenue estimates two times [2] Stock Performance - BOK Financial shares have declined approximately 14.4% since the beginning of the year, while the S&P 500 has decreased by 10.2% [3] - The current estimate revisions trend for BOK Financial is unfavorable, resulting in a Zacks Rank 4 (Sell) for the stock, indicating expected underperformance in the near future [6] Future Outlook - The current consensus EPS estimate for the upcoming quarter is $2.10 on revenues of $533.8 million, and for the current fiscal year, it is $8.60 on revenues of $2.16 billion [7] - The outlook for the industry, particularly the Banks - Southwest sector, is favorable, ranking in the top 11% of over 250 Zacks industries, suggesting potential for better performance compared to lower-ranked industries [8]

Core Viewpoint - Washington Trust Bancorp reported quarterly earnings of $0.61 per share, which missed the Zacks Consensus Estimate of $0.62 per share, and is a decrease from $0.64 per share a year ago [1] Earnings Performance - The earnings surprise for the quarter was -1.61%, while the previous quarter had a positive surprise of 1.72% with actual earnings of $0.59 per share against an expectation of $0.58 [2] - Over the last four quarters, Washington Trust has surpassed consensus EPS estimates three times [2] Revenue Performance - The company posted revenues of $59.07 million for the quarter, exceeding the Zacks Consensus Estimate by 11.50%, and up from $48.83 million year-over-year [3] - Washington Trust has topped consensus revenue estimates four times over the last four quarters [3] Stock Performance - Washington Trust shares have declined approximately 13.2% since the beginning of the year, compared to a decline of 10.2% for the S&P 500 [4] Future Outlook - The earnings outlook for Washington Trust is mixed, and the current consensus EPS estimate for the upcoming quarter is $0.69 on revenues of $54.88 million, while the estimate for the current fiscal year is $2.76 on revenues of $220.17 million [8] - The Zacks Rank for Washington Trust is currently 3 (Hold), indicating expected performance in line with the market in the near future [7] Industry Context - The Banks - Northeast industry, to which Washington Trust belongs, is currently in the top 23% of over 250 Zacks industries, suggesting a favorable outlook compared to the bottom 50% [9]

分组1 - UnitedHealth Group reported quarterly earnings of $7.20 per share, missing the Zacks Consensus Estimate of $7.27 per share, but showing an increase from $6.91 per share a year ago, resulting in an earnings surprise of -0.96% [1] - The company posted revenues of $109.58 billion for the quarter ended March 2025, missing the Zacks Consensus Estimate by 1.40%, compared to $99.8 billion in the same quarter last year [2] - UnitedHealth shares have increased by approximately 15.7% since the beginning of the year, contrasting with the S&P 500's decline of -10.3% [3] 分组2 - The current consensus EPS estimate for the upcoming quarter is $7.56 on revenues of $111.99 billion, and for the current fiscal year, it is $29.73 on revenues of $451.65 billion [7] - The Medical - HMOs industry, to which UnitedHealth belongs, is currently ranked in the top 36% of over 250 Zacks industries, indicating a favorable outlook for the sector [8] - Another competitor in the same industry, Humana, is expected to report quarterly earnings of $9.98 per share, reflecting a year-over-year increase of +38%, with revenues projected at $32.22 billion, up 9.8% from the previous year [9]

分组1 - Kinder Morgan reported quarterly earnings of $0.34 per share, missing the Zacks Consensus Estimate of $0.35 per share, representing an earnings surprise of -2.86% [1] - The company posted revenues of $4.24 billion for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 2.53%, compared to year-ago revenues of $3.84 billion [2] - Over the last four quarters, Kinder Morgan has not surpassed consensus EPS estimates, topping revenue estimates just once [2] 分组2 - The stock has lost about 0.7% since the beginning of the year, while the S&P 500 has declined by -8.3% [3] - The company's earnings outlook is crucial for investors, including current consensus earnings expectations for upcoming quarters [4] - The current consensus EPS estimate for the coming quarter is $0.27 on $3.88 billion in revenues, and $1.28 on $16.4 billion in revenues for the current fiscal year [7] 分组3 - The Zacks Industry Rank for Oil and Gas - Production and Pipelines is currently in the bottom 36% of over 250 Zacks industries, indicating potential challenges for stock performance [8] - Another company in the same industry, Pembina Pipeline, is expected to report quarterly earnings of $0.53 per share, reflecting a year-over-year change of -1.9% [9] - Pembina Pipeline's revenues are projected to be $1.6 billion, up 39.8% from the year-ago quarter [10]

Progressive (PGR) came out with quarterly earnings of $4.65 per share, missing the Zacks Consensus Estimate of $4.72 per share. This compares to earnings of $3.73 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -1.48%. A quarter ago, it was expected that this insurer would post earnings of $3.43 per share when it actually produced earnings of $4.08, delivering a surprise of 18.95%.Over the last four quarters, the company has s ...

Group 1: Earnings Performance - Farmers National Banc (FMNB) reported quarterly earnings of $0.39 per share, exceeding the Zacks Consensus Estimate of $0.34 per share, and showing an increase from $0.34 per share a year ago, representing an earnings surprise of 14.71% [1] - The company posted revenues of $44.68 million for the quarter ended March 2025, which was 0.39% below the Zacks Consensus Estimate, compared to $40.04 million in revenues from the same quarter last year [2] Group 2: Stock Performance and Outlook - Farmers National shares have declined approximately 14.8% since the beginning of the year, while the S&P 500 has decreased by 8.3% [3] - The current consensus EPS estimate for the upcoming quarter is $0.35 on revenues of $45.2 million, and for the current fiscal year, it is $1.43 on revenues of $182.5 million [7] Group 3: Industry Context - The Banks - Midwest industry, to which Farmers National belongs, is currently ranked in the top 12% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8]

Company Performance - Applied Digital Corporation reported a quarterly loss of $0.16 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.11, and an improvement from a loss of $0.52 per share a year ago [1] - The company posted revenues of $52.92 million for the quarter ended February 2025, missing the Zacks Consensus Estimate by 16.75%, but showing an increase from $43.35 million in the same quarter last year [2] - Over the last four quarters, the company has surpassed consensus EPS estimates only once [2] Stock Movement and Outlook - Applied Digital Corporation shares have declined approximately 30.8% since the beginning of the year, compared to a decline of 8.8% for the S&P 500 [3] - The company's earnings outlook is mixed, with current consensus EPS estimates at -$0.11 on revenues of $77.43 million for the upcoming quarter and -$0.96 on revenues of $252.89 million for the current fiscal year [7] Industry Context - The Financial - Miscellaneous Services industry, to which Applied Digital Corporation belongs, is currently ranked in the top 19% of over 250 Zacks industries, indicating a favorable outlook compared to lower-ranked industries [8]

Company Performance - Orchestra BioMed Holdings, Inc. reported a quarterly loss of $0.43 per share, which aligns with the Zacks Consensus Estimate, compared to a loss of $0.37 per share a year ago [1] - The company posted revenues of $0.25 million for the quarter ended December 2024, missing the Zacks Consensus Estimate by 67.85%, and down from $0.26 million year-over-year [2] - Over the last four quarters, the company has surpassed consensus EPS estimates two times and topped consensus revenue estimates just once [2][1] Stock Movement and Outlook - Shares of Orchestra BioMed Holdings, Inc. have increased by approximately 10% since the beginning of the year, contrasting with a decline of -5.1% in the S&P 500 [3] - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The current consensus EPS estimate for the coming quarter is -$0.46 on revenues of $0.74 million, and for the current fiscal year, it is -$1.95 on revenues of $3.84 million [7] Industry Context - The Medical - Biomedical and Genetics industry, to which Orchestra BioMed belongs, is currently ranked in the top 27% of over 250 Zacks industries, indicating a favorable outlook [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact stock performance [5]

Company Performance - Vivos Therapeutics, Inc. reported a quarterly loss of $0.28 per share, which was better than the Zacks Consensus Estimate of a loss of $0.43, and a significant improvement from a loss of $3.05 per share a year ago, resulting in an earnings surprise of 34.88% [1] - The company posted revenues of $3.7 million for the quarter ended December 2024, missing the Zacks Consensus Estimate by 5.18%, but showing an increase from year-ago revenues of $3.25 million [2] - Over the last four quarters, Vivos Therapeutics has surpassed consensus EPS estimates two times, but has not been able to beat consensus revenue estimates during the same period [2] Stock Performance - Vivos Therapeutics shares have declined approximately 27.5% since the beginning of the year, compared to a decline of 5.1% for the S&P 500 [3] - The current consensus EPS estimate for the upcoming quarter is -$0.41 on revenues of $4.1 million, and for the current fiscal year, it is -$1.43 on revenues of $18.3 million [7] Industry Outlook - The Medical - Drugs industry, to which Vivos Therapeutics belongs, is currently ranked in the top 31% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact Vivos Therapeutics' stock performance [5]